BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
BioAge Labs, Inc.NASDAQ: BIOA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation grows in line with its trailing trend
Q1 FY2026 stock-based compensation of $4.26M rose 44.3% year over year, ahead of the +43.2% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 56.4% from the prior quarter. Over 3 fiscal years it compounded at +66.3% a year.
Context
- Stock-based compensation amounted to 130.0% of revenue in FY2025.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +44.3% holds above the trailing-twelve-month pace of +43.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 11.69M USD
- Year-over-year change
- +67.5%
- 3-year CAGR
- +66.3%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.69M | +67.5% |
| FY2024 | 2024-12-31 | 6.98M | +131.4% |
| FY2023 | 2023-12-31 | 3.02M | +18.7% |
| FY2022 | 2022-12-31 | 2.54M | — |
Stock-Based Compensation vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +43.2% is the 3rd highest of 9, against a peer median of -17.1%.
- Stock-based compensation amounts to 126.0% of revenue for BIOA, versus a peer median of 5.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $33.74M USD | -35.1% | -23.4% | — | |
| LTM Mar 2026 | $21.03M USD | +1.0% | +44.8% | — | |
| LTM Mar 2026 | $17.5M USD | -62.1% | -23.7% | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $13M USD | +43.2% | +66.3% | 126.0% |
| LTM Mar 2026 | $10.44M USD | +45.6% | +16.4% | 517.7% | |
| LTM Mar 2026 | $9.12M USD | -45.7% | -30.1% | 23.6% | |
| LTM Mar 2026 | CA$7.29M CAD | -36.7% | -24.4% | 2.3% | |
| LTM Mar 2026 | $5.91M USD | — | +57.3% | 4.4% | |
| LTM Mar 2026 | CA$4.6M CAD | +209.3% | -38.3% | 1.5% | |
| LTM Mar 2026 | $2.42M USD | +1.9% | -2.6% | 5.8% | |
| Peer median (excluding BIOA) | — | -17.1% | -23.4% | 5.1% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.